Items where Author is "Wagner, Anita K."

Davis, Courtney, Wagner, Anita K., Mintzes, Barbara, Scowcroft, Henry, Woloshin, Steven and Naci, Huseyin ORCID: 0000-0002-7192-5751 (2024) Patients deserve better information on new drugs. BMJ (Clinical research ed.), 387. ISSN 0959-8146

Shahzad, Mahnum, Naci, Huseyin ORCID: 0000-0002-7192-5751, Esselen, Katharine M., Dottino, Joseph A. and Wagner, Anita K. (2024) Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. Journal of Pharmaceutical Policy and Practice, 17 (1). ISSN 2052-3211

Naci, Huseyin ORCID: 0000-0002-7192-5751, Zhang, Yichen, Woloshin, Steven, Guan, Xiaodong, Xu, Ziyue and Wagner, Anita K. (2024) Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. The Lancet Oncology, 25 (6). 760 - 769. ISSN 1470-2045

Wei, Yuxuan, Zhang, Yichen, Xu, Ziyue, Wang, Guoan, Zhou, Yue, Li, Huangqianyu, Shi, Luwen, Naci, Huseyin ORCID: 0000-0002-7192-5751, Wagner, Anita K. and Guan, Xiaodong (2024) Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. The Lancet Regional Health - Western Pacific, 45. ISSN 2666-6065

Ivama-Brummell, Adriana M., Marciniuk, Fernanda L, Wagner, Anita K., Osorio-de-Castro, Claudia G. S., Vogler, Sabine, Mossialos, Elias ORCID: 0000-0001-8664-9297, Tavares-de-Andrade, Carla L. and Naci, Huseyin ORCID: 0000-0002-7192-5751 (2023) Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis. The Lancet Regional Health - Americas, 22. ISSN 2667-193X

Davis, Courtney, Wagner, Anita K., Salcher-Konrad, Maximilian ORCID: 0000-0002-5628-5266, Scowcroft, Henry, Mintzes, Barbara, Pokorny, Adrian M J, Lew, Jianhui and Naci, Huseyin ORCID: 0000-0002-7192-5751 (2023) Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ, 380. e073711. ISSN 0959-8138

Shahzad, Mahnum, Naci, Huseyin ORCID: 0000-0002-7192-5751 and Wagner, Anita K. (2023) Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. JAMA, 329 (9). 760 - 761. ISSN 0098-7484

Zhang, Yichen, Naci, Huseyin ORCID: 0000-0002-7192-5751, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen and Guan, Xiaodong (2022) Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA network open, 5 (8). ISSN 2574-3805

Fu, Mengyuan, Naci, Huseyin ORCID: 0000-0002-7192-5751, Booth, Christopher M., Gyawali, Bishal, Cosgrove, Austin, Toh, Sengwee, Xu, Ziyue, Guan, Xiaodong, Ross-Degnan, Dennis and Wagner, Anita K. (2021) Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 181 (12). 1596 - 1604. ISSN 2168-6106

Naci, Huseyin ORCID: 0000-0002-7192-5751, Guan, Xiaodong, Woloshin, Steven, Xu, Ziyue and Wagner, Anita K. (2021) Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. JAMA Internal Medicine, 181 (11). 1521 - 1522. ISSN 2168-6106